Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte Inc (NQ: HUMA )

5.640 +0.020 (+0.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Humacyte Inc

< Previous 1 2 3 4 Next >
Recap: Humacyte Q1 Earnings
Via Benzinga
Earnings Outlook For Humacyte
Via Benzinga
Earnings Scheduled For March 24, 2023
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter. • Caledonia Mining (AMEX:CMCL) is projected to report earnings for its fourth... 
Via Benzinga
Earnings Preview For Humacyte
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Humacyte's Return on Invested Capital Insights
Via Benzinga
Humacyte Posts Preclinical Data Of Small-Diameter Human Acellular Vessel In Bypass Grafting
Humacyte Inc (NASDAQ: HUMA) has announced  
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 115 stocks hit new 52-week lows. 
Via Benzinga
Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones dropping around 70 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 34 companies set new 52-week lows. 
Via Benzinga
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Humacyte Earnings Perspective: Return On Invested Capital
According to Benzinga Pro, during Q2, Humacyte (NASDAQ:HUMA) earned $36.87 million, a 285.9% increase from the preceding quarter. Humacyte also posted a total of $1.30 million in sales, a 458.37%... 
Via Benzinga
Earnings Scheduled For August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
95 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 100.4% to close at $4.75 on Monday after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
52 Stocks Moving In Monday's Mid-Day Session
Gainers DiDi Global Inc. (NYSE: DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users. 
Via Benzinga
41 Stocks Moving In Monday's Mid-Day Session
Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results. 
Via Benzinga
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. 
Via Benzinga
Earnings Scheduled For May 13, 2022
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Humacyte's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Humacyte (NASDAQ:HUMA) posted Q4 earnings of $42.59 million, an increase from Q3 of 234.92%. Sales dropped to $177.00 thousand, a 26.56% decrease between quarters. 
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
How To Attend Humacyte Q4 2021 Earnings Conference Call
Humacyte (NASDAQ:HUMA) will host a conference call at 08:00 AM ET on March 29, 2022, to discuss Q4 2021 earnings results. How to Attend Humacyte (HUMA) Conference Call Follow this... 
Via Benzinga
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million. 
Via Benzinga
Humacyte's Human Acellular Vessel Shows Long Term Benefit In Hemodialysis Patients
Humacyte Inc (NASDAQ: HUMA) announced five-year data from a Phase 2 trial of Human Acellular Vessel (HAV) for arteriovenous (AV) access in hemodialysis. In the... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.